SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Spyre reported positive Phase 2 SKYLINE data for SPY003, a potential best-in-class anti-IL-23. The results met its endpoints with clinically meaningful improvements and a well-tole…
Soluna Holdings, Inc. energized the final 14 MW of its Project Kati 1 in Texas, and has received a conditional Base Load classification from ERCOT for the full 166 MW Kati campus.
X4 Pharmaceuticals secured FDA agreement to reduce its late-stage trial enrollment by 126 patients, with data expected mid-2028. This regulatory alignment supports the company's ex…
Monte Rosa Therapeutics announced a $50 million milestone payment from collaborator Novartis regarding a global Phase 2 clinical study of MRT-6160 for Sjogren's disease, validating…
Nova Minerals received critical processing equipment to construct its planned antimony refining facility in Alaska, funded by a Department of Defense award and advancing production…
The FDA is taking steps to maintain access to life-saving neonatal starter parenteral nutrition following concerns over a potential supply gap, aligning with the administration's c…
The FDA grants accelerated approval to a new breast cancer treatment for adult patients, advancing medical innovation and expanding treatment options.
The company issued an internal update regarding the draft of the proxy statement and its previously announced strategic restructuring plan. The filing was made to correct informati…
The Trust approved new bylaws reducing the requirement for annual shareholder meetings and modifying how special meetings can be called.
CEA Industries Inc. filed an exhibit amending its Articles of Incorporation with the Nevada Secretary of State, a routine regulatory update.
Novartis reported the Lp(a)HORIZON Phase 3 trial for competitor pelacarsen did not meet its primary endpoint of reducing cardiovascular events, while Ionis continues independent co…
The company disclosed an unavoidable delay to file its annual report. To ensure compliance with investor communication obligations, Fusemachines plans to distribute a corporate upd…
The healthcare company updated its Adjusted EBITDA and EBITDAR definitions in its 2025 10-K filing. This provides investors with standardized, comparable figures for financial anal…
CBIZ CPAs P.C. confirmed agreement with Irenic Acquisition Corp.'s Company statement regarding its Form 8-K filed on September 4, 2026. It is a management agreement used to provide…
The Federal Reserve Board has terminated enforcement actions against United Texas Bank, Quontic Bank Acquisition Corp., and Quontic Bank Holdings Corp. The order vacates a consent …
DynaResource received US$4 million from Mexican tax authorities following a resolution. The cash inflow signals progress in recovering a larger outstanding receivable balance.
Ramaco explained that a planned one-million-share distribution by Yorktown Energy Partners is likely responsible for negative trading activity on September 3, 2026. Market analysts…
The FDA has approved Ionis Pharmaceuticals' ZANVASTRO, the first disease-modifying therapy for Alexander disease. This approval marks Ionis' second independent launch of the year a…
The FDA has approved Zanvastro injection for treating Alexander disease in pediatric and adult patients.
Rainier Acquisition Corp. filed a consented financial statement as of August 28, 2026. The company maintains a trust balance of $75 million and total assets of $76.1 million.